7 completed, 1 active not recruiting, 1 not yet recruiting. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 7, Active not recruiting 1, Not yet recruiting 1 |
Follow Dose 1: new trials by email Literature Review of Dose 1 trials Research Report on Dose 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet Dose 1, Dose 2 - Food Effect in Healthy Volunteers, Weight Management | Phase 1 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 72 | 2026-11-03 | 2026-11-13 |
| Safety, Tolerability and Pharmacokinetics of ETD-001 Gel Dose 1, dose 2, dose 3 - Safety Issues | Phase 1 | Completed | Etern Therapeutics Wuxi Limited | 56 | 2026-03-16 | 2026-09-10 |
| Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 AZD6234 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 24 | 2025-02-24 | 2025-11-03 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 AZD5004 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 33 | 2024-12-19 | 2025-10-15 |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 AZD5004 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 16 | 2024-12-17 | 2025-06-08 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 AZD0780 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 16 | 2024-08-08 | 2026-11-10 |
| Vitamin D Levels Following Topical Application of Vitamin D Ointment Dose 1, Dose 2 - Vitamin D Deficiency | Phase 1 | Completed | University of Minnesota | 10 | 2016-03-01 | 2019-11-01 |
| Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Dose 1, Dose 2, Dose 0 - Diabetes Prevention | Phase 1 | Completed | Pennington Biomedical Research Center | 64 | 2014-02-01 | 2019-03-21 |
| Transfer of Genetically Engineered Lymphocytes in Melanoma Patients Dose 1, Dose 2, Dose 3 - Melanoma | Phase 1 | Active not recruiting | Loyola University | 14 | 2012-07-01 | 2020-10-30 |
Renal Insufficiency (2) · Melanoma (1) · Obesity (1) · Vitamin D Deficiency (1)
AstraZeneca (4) · Etern Therapeutics Wuxi Limited (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · Loyola University (1) · Pennington Biomedical Research Center (1) · University of Minnesota (1)
United States (7) · China (2)
Fadi Saba, M.D. (1) · Jennifer C Rood, Ph.D. (1) · Joel M Neutel, M.D. (1) · Kevin A Peterson, MD, MPH (1) · Kwabena Ayesu, M.D. (1) · Michael Nishimura, PhD (1) · Thomas C Marbury, M.D. (1) · Yiwen Zhang (1)
P01CA154778 (1), P50AT002776 (1), R44CA126461 (1)